AprilBio Co.,Ltd. Logo

AprilBio Co.,Ltd.

Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.

397030 | KO

Overview

Corporate Details

ISIN(s):
KR7397030008
LEI:
Country:
South Korea
Address:
강원도 춘천시 강원대학길 1 의생명과학대학 B동 602호, 춘천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AprilBio Co., Ltd. is a clinical-stage biotechnology company that develops innovative biologic drugs. The company's operations are centered on its proprietary SAFA™ (anti-Serum Albumin Fab Associated) platform technology, a long-acting protein engineering solution. The SAFA platform utilizes an albumin binder to extend the half-life of antibody fragments, enhancing their efficacy and safety. AprilBio's research and development pipeline is focused on creating novel therapeutics, branded as SAFAbody™, primarily for the treatment of autoimmune diseases and oncology. The company aims to address unmet medical needs by advancing drug candidates through early clinical development stages for subsequent technology transfer or licensing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Share Issue/Capital Change
전환청구권행사 (제1회차)
Korean 11.8 KB
2025-09-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 180.5 KB
2025-09-12 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-09-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-08-13 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.7 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-06 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-05-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 905.7 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.6 KB

Automate Your Workflow. Get a real-time feed of all AprilBio Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AprilBio Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AprilBio Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea
358570

Talk to a Data Expert

Have a question? We'll get back to you promptly.